Views & Analysis Immuno-oncology drugs: key to the Cancer Moonshot? Assessing the global challenges inhibiting immuno-oncology market access.
Partner Content Partner Content Managing Multi-Arm Studies in an Evolving Immuno-Oncology La... Collaborate with CROs and sites to help minimize risks
Partner Content Partner Content Beyond Immunotherapies Latest innovations emerging from immunotherapy research
News Merck KGaA to develop immunotherapies with F-star German Merck has option to licence LAG3-PDL1 drug.
Views & Analysis The cancer challenge: the quest for a cure is only half the ... The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
News Takeda signs deal with UK biotech GammaDelta Therapeutics on... UK biotech pioneering new type of T cell immunotherapy
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
